Meeder Asset Management Inc Reata Pharmaceuticals Inc Transaction History

Meeder Asset Management Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$79.22 - $105.37 $21,151 - $28,133	267 New	267 $27,000
Q4 2021 Feb 11, 2022	SELL	$25.61 - $110.96 $281 - $1,220	-11 Closed	0 $0
Q3 2020 Nov 02, 2020	SELL	$93.53 - $163.34 $3,273 - $5,716	-35 Reduced 76.09%	11 $1,000
Q2 2020 Aug 11, 2020	SELL	$126.3 - $176.56 $505 - $706	-4 Reduced 8.0%	46 $7,000
Q1 2020 May 15, 2020	SELL	$124.16 - $247.74 $110,502 - $220,488	-890 Reduced 94.68%	50 $7,000
Q4 2019 Feb 13, 2020	BUY	$74.57 - $217.92 $70,095 - $204,844	940 New	940 $193,000
Q3 2019 Oct 17, 2019	SELL	$71.26 - $95.75 $25,653 - $34,470	-360 Closed	0 $0
Q2 2019 Aug 05, 2019	SELL	$77.72 - $94.35 $34,196 - $41,514	-440 Reduced 55.0%	360 $34,000
Q1 2019 Apr 16, 2019	SELL	$51.9 - $101.79 $34,721 - $68,097	-669 Reduced 45.54%	800 $69,000
Q4 2018 Jan 17, 2019	BUY	$48.76 - $76.44 $27,110 - $42,500	556 Added 60.9%	1,469 $82,000
Q3 2018 Nov 02, 2018	BUY	$35.64 - $92.06 $32,539 - $84,050	913 New	913 $0
Q1 2018 May 03, 2018	SELL	$20.0 - $30.19 $1,060 - $1,600	-53 Closed	0 $0
Q3 2017 Oct 20, 2017	BUY	$26.29 - $31.88 $1,393 - $1,689	53	53 $2,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.